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Abstract
Background: Used as contrast agents for brain magnetic resonance imaging (MRI), markers for beta-amyloid deposits might
allow early diagnosis of Alzheimer’s disease (AD). We evaluated the cost-effectiveness of such a diagnostic test, MRI+CLP
(contrastophore-linker-pharmacophore), should it become clinically available.
Methodology/Principal Findings: We compared the cost-effectiveness of MRI+CLP to that of standard diagnosis using
currently available cognition tests and of standard MRI, and investigated the impact of a hypothetical treatment efficient in
early AD. The primary analysis was based on the current French context for 70-year-old patients with Mild Cognitive
Impairment (MCI). In alternative ‘‘screen and treat’’ scenarios, we analyzed the consequences of systematic screenings of
over-60 individuals (either population-wide or restricted to the ApoE4 genotype population). We used a Markov model of
AD progression; model parameters, as well as incurred costs and quality-of-life weights in France were taken from the
literature. We performed univariate and probabilistic multivariate sensitivity analyses. The base-case preferred strategy was
the standard MRI diagnosis strategy. In the primary analysis however, MRI+CLP could become the preferred strategy under a
wide array of scenarios involving lower cost and/or higher sensitivity or specificity. By contrast, in the ‘‘screen and treat’’
analyses, the probability of MRI+CLP becoming the preferred strategy remained lower than 5%.
Conclusions/Significance: It is thought that anti-beta-amyloid compounds might halt the development of dementia in
early stage patients. This study suggests that, even should such treatments become available, systematically screening the
over-60 population for AD would only become cost-effective with highly specific tests able to diagnose early stages of the
disease. However, offering a new diagnostic test based on beta-amyloid markers to elderly patients with MCI might prove
cost-effective.
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Introduction
Alzheimer’s disease (AD) is the main cause of dementia in older
people, with approximately 26 million cases worldwide [1,2,3].
What is more, a major increase in this prevalence is expected in
years to come [3]. In France, while 850.000 people were
diagnosed with AD in 2004, 2.1 million may be affected by
2040 [4].
There are currently no treatments that may cure AD or halt the
course of the disease. However, in recent years, drugs such as
acetylcholinesterase inhibitors have demonstrated efficacy at
reducing the intensity of certain symptoms. Moreover, new
avenues for research are being investigated. Many scientists
believe that one of the main causes of the AD has to do with beta-
amyloid, microscopic protein which accumulate throughout the
cortex of Alzheimer patients. This is called the ‘‘amyloid
hypothesis’’ [2]. They believe that the destruction of brain cells
seen in AD is caused by defects in the way beta-amyloid is
produced, how it accumulates and how it is eliminated. Animal
studies in mice have suggested that anti-beta-amyloid drugs can
reduce brain amyloid level and improve memory problems in
diseases similar to AD. At the present time, there is no clear
evidence that these drugs can improve Alzheimer symptoms or
protect brain cells but it is thought that they could halt the
development of dementia in patients with early stage AD [5].
With these prospects of further therapeutic developments,
attention has now focused on improving the sensitivity and
specificity of diagnostic tools, and in developing tools that would
allow early diagnosis.
The current standard diagnostic strategy of AD generally
comprises a detailed history, a standardized assessment of
cognition and functional status and laboratory testing. Brain
imaging examinations such as nonenhanced computed tomogra-
phy imaging, positron emission tomography imaging, or magnetic
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resonance imaging (MRI) are also sometimes used in order to
exclude other conditions or to measure brain atrophy.
Finding more accurate diagnostic tools implies discovering non-
invasive sensitive and specific biomarkers for AD. One avenue of
research lies in the detection of b-amyloid plaques [6,7]. This
detection could be achieved through the use of new contrast agents
for MRI which bind to b-amyloid plaques, thus allowing a valid
diagnosis of AD at a very early stage [6,8].
A few studies have attempted to assess the cost-effectiveness of
imaging diagnosis tools for AD [9,10,11], or to evaluate the impact
of screening the general population [12]. However, none has
focused on combinations of MRI and new contrast agents.
In this study, we evaluate the cost-effectiveness of a diagnostic
strategy based on MRI with a new contrast agent detecting b-
amyloid plaques (contrastophore-linker-pharmacophore or CLP).
We compare this strategy with other current standard diagnostic
strategies. In the primary analysis, the new strategy is simply
introduced as an alternative to current diagnostic tools and made
available to the same population. In this setting, we investigate the
consequences of the introduction of a new AD treatment with
significant efficacy at an early stage of the disease.
In alternative scenarios, we assume that the availability of this
new treatment would naturally raise the issue of the opportunity of
screening for AD. We thus evaluate the cost-effectiveness of
diagnostic strategies in the context of hypothetical national
screening programs.
Methods
1. Framework of the cost-effectiveness analyses
We performed cost-effectiveness analyses in order to compare
the costs and benefits of several alternative diagnostic strategies in
the French context. Costs were measured in Euros (J) and benefits
were measured in quality-adjusted life-years (QALYs), which
assign to each year of life a weight between 0 (dead) and 1 (perfect
health).
A strategy was considered dominated if another strategy had a
better or similar efficacy at a lower cost; conversely, a strategy was
considered strongly dominant when it was both more effective and
cheaper than all other strategies. We computed incremental cost-
effectiveness ratios (ICERs), in which changes in resource use,
compared with the next best strategy, were included in the
numerator, while additional health effects, compared with the next
best strategy, were included in the denominator. Finally, we
compared ICERs to the willingness-to-pay (WTP) for an
additional QALY, which was assumed equal to three times the
gross national product per capita in France, as recommended by
the World Health Organization Choice working group [13,14],
that is, 76.171J per QALY in 2009. If no strategy was strongly
dominant, the preferred strategy was that with the highest ICER
under the willingness-to-pay threshold.
The study was conducted from a societal perspective, meaning it
included all costs and benefits, no matter who incurred them.
Future costs and QALYs were discounted at 5% annually.
The cost-effectiveness analyses were conducted using the
TreeAge software [15]. We performed expected value analyses,
based on the computation over simulated cycles of percentages of
a hypothetical cohort in each modeled AD stage. For the
multivariate sensitivity analyses, we also performed Monte Carlo
simulations with 10.000 trials, in order to derive the distribution of
incremental cost-effectiveness ratios for the MRI+CLP strategies,
as well as acceptability curves for all strategies.
Table 1 details the compared strategies.
1.1. Primary analysis. In the primary analysis, three
diagnostic strategies were compared over a three year period for
a cohort of 70 year-old individuals consulting for the first time
following mild cognitive impairment (MCI) symptoms:
– the standard diagnosis strategy based on an interview with an
AD specialist, cognition tests such as mini-mental state
evaluation (MMSE) and laboratory tests (standard diagnosis
strategy)
– a strategy combining the standard strategy with standard MRI
(standard MRI strategy)
– and a strategy combining the standard strategy with MRI used
with a new contrast agent detecting b-amyloid plaques
(MRI+CLP strategy)
Figure 1A depicts the tree showing the possible outcomes of
using one of the investigated diagnostic tests in this scenario. The
choice of a 3-year horizon for this analysis was motivated by data
on the duration of efficacy of currently available AD treatments
and mortality rates of over-70 dementia patients.
As part of the sensitivity analysis, we assumed that a new
treatment had been developed which delayed significantly the
course of AD at an early stage and that this treatment was offered
to MCI patients diagnosed with AD but with high MMSE scores
(who were either false positives or early AD patients).
1.2. ‘‘Screen and treat’’ analyses. In the ‘‘screen and
treat’’ analyses, it was assumed that a new treatment had been
developed which delayed significantly the course of AD at an early
stage, and that a national screening campaign targeted at
individuals over 60 years-old took place. Screening could either
be population-wide or limited to individuals carrying the e4 allele
of the apolipoprotein E gene (ApoE4), in whom the risk of AD has
been shown to be significantly higher [16].
In this context, three diagnostic strategies were compared over a
fifteen year period for a cohort of 60 year-old individuals taking
part in the screening campaign:
– the standard diagnosis strategy,
– the standard MRI,
– and the MRI+CLP strategy
Figure 1B depicts the tree showing the possible outcomes of the
screening procedure with one of the investigated diagnostic tests in
this scenario.
Following the initial screening, individuals who were not
diagnosed as AD patients were screened again every 5 years,
unless they developed dementia symptoms between these sched-
uled screenings, in which case they were immediately tested.
The choice of a 15 year horizon for this second analysis was
motivated by the need to follow 60 year-old mostly healthy
individuals through several screening campaigns.
2. Models of disease progression
We used a Markov model of the evolution of AD based on
previous work [17] in which the disease evolved in 5 stages: no
AD, mild AD, moderate AD, severe AD and death. For the screen
and treat analyses, a 6th stage was added for asymptomatic patients
with early AD. We also distinguished patients that were taken care
of at home from institutionalized patients, at each stage of AD.
Initially, all patients in the cohort began in the community setting
and had a probability in each cycle, conditional on disease state
(and, for the 2d analysis, on age), of making a transition to nursing
home care. File S1 and Figure S1 present the models we used in
more detail.
Cost-Effectiveness of MRI+CLP for Alzheimer’s
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Considering the natural history of AD, we chose to model
disease progression using 6 month cycles. Transition probabilities
over 6 months were obtained from the square root of the matrix of
annual transition probabilities which were based on the literature
[17,18,19] and available data on age-specific mortality rates [20]
and age-specific AD incidence [4] in France.
Table S1 lists all model parameters, with their base-case values.
Table 1. Compared strategies.
Strategy Tests Imaging
Standard diagnosis Laboratory tests, clinical examination, cognition test None
Standard MRI Laboratory tests, clinical examination, cognition test Non-enhanced MRI
MRI+CLP Laboratory tests, clinical examination, cognition test MRI with a new contrast agent detecting b-amyloid plaques
doi:10.1371/journal.pone.0035559.t001
Figure 1. Decision tree for an individual tested for Alzheimer’s disease (AD). Possible outcomes of the testing procedure are depicted as a
function of the individual’s health status for: (a) The primary scenario (testing of over-70 patients consulting for dementia symptoms). (b) The ‘‘screen
and treat’’ scenario (systematic screening of the over-60 population). Depending on the investigated strategy, the generic ‘‘diagnostic test’’
mentioned in the trees may be standard diagnosis, standard MRI or MRI+CLP. When AD is diagnosed, the imaging procedures are followed by a
cognition test (MMSE) in order to determine the disease stage. No test is performed in severe AD patients, who are assumed to be diagnosed directly.
doi:10.1371/journal.pone.0035559.g001
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3. Available treatments
The model assumes that all patients who receive a diagnosis of
probable Alzheimer disease receive treatment with donepezil,
memantine or a hypothetical higher-efficacy drug.
If the patient is diagnosed at a mild or moderate stage,
donepezil is prescribed, to be replaced by memantine when the
patient has evolved to a severe stage of AD. If the patient is
diagnosed when the disease is already severe, memantine is
prescribed.
In addition, a hypothetical treatment T which is efficient at
early stages of AD may be prescribed to patients who are
diagnosed with AD but have high MMSE scores in the primary
analysis, or to patients who are diagnosed with early AD in the
‘‘screen and treat’’ analyses.
Donepezil treatment has been shown to improve significantly
memory and other cognitive functions in patients with mild to
moderate AD [21], and to reduce the annual decline in cognition
in these patients when compared with patients in a placebo group
[22]; similarly, memantine treatment has been shown to cause a
clinically noticeable reduction in deterioration over 28 weeks,
compared with placebo, in patients with moderate-to-severe AD
[23,24]. It is to be noted that actually, donepezil or memantine
help treat the symptoms of AD although there is no evidence that
they modify the underlying pathology of the disease. On the basis
of these data, we assumed that treatment modified transition
probabilities between disease stages, both reducing the speed of
AD progression and increasing the chance of symptom lessening
(Table S1). For treatment T, we only assumed a decrease in the
progression from early to mild and moderate stage AD, as we
supposed that reversal to asymptomatic AD of mild stage patients
was not possible. In the base-case analysis, these effects were
assumed to be constant throughout the duration of treatment;
long-term clinical studies suggest that treatment efficacy may last
for up to 3 years [21,25].
4. AD prevalence and incidence
In the primary analysis, the simulated cohort comprised 70 year
old individuals who consulted for cognitive impairment symptoms.
There is evidence that older persons with Mild Cognitive
Impairment (MCI) feature neurobiological AD in 50% to 70%
of the cases [26]. Based on this evidence and on data from a study
at Massachusetts General Hospital [10], we estimated that 56% of
the cohort patients had AD initially. The distribution between
disease stages at this first consultation was estimated, based on a
French study [27], at 55.9% mild stage AD, 39.9% moderate stage
AD and 4.2% severe stage AD.
MCI is often a precursor to Alzheimer’s dementia and the
annual rate of development of AD for patients with MCI is 10 to
15% [26,28]. Here, we assumed a 10%/year AD incidence in
untreated patients of the cohort.
In the first ‘‘screen and treat’’ analysis, the cohort was
representative from the French population of individuals over 60
years old, as it was assumed that a national screening was
underway. Therefore the initial prevalence of AD (including early
asymptomatic stage AD) in the cohort was assumed to be 1% [3].
We further assumed that there was an 8/7 ratio between the
prevalences of early stage and mild stage AD [Personal
communication, Pr. Verny, AP-HP, Paris, 2009]. The distribution
between mild, moderate and severe stages was the same as in the
primary analysis.
Age-specific AD incidence rates for individuals between 60 and
75 years old were chosen to be consistent with data from recent
cohort studies [29,30].
In the second ‘‘screen and treat’’ analysis, screening was
restricted to individuals carrying the e4 allele of the apolipoprotein
E gene (ApoE4). Based on earlier studies showing significantly
higher risk of AD occurrence in ApoE4 individuals [16], we
assumed that age-specific incidence rates were doubled.
5. Diagnostic tests
The standard diagnostic strategy of AD was assumed to
comprise a detailed history of the patient, an assessment of
cognition and functional status using a questionnaire test such as
the MMSE, and laboratory testing. Other strategies combined
MRI (with or without a new contrast agent) for AD diagnosis with
a questionnaire test such as the MMSE aimed at determining the
stage of the disease.
In the case of severe AD, it was assumed that dementia
symptoms allowed direct diagnosis over a consultation (without
need for a diagnostic test). Hence, all severe stage AD patients
were assumed to be diagnosed and to receive treatment.
As in [10], we estimated the sensitivity of the standard
diagnostic tests at 75% and their specificity at 90%; in early stage
AD, we assumed that patients were asymptomatic and that the
standard diagnostic therefore performed as it did in non-AD
patients, declaring only 10% ( = 120.9) of them as having AD.
Based on data from a clinical study, we also hypothesized a
sensitivity of 50% in early stage, 88% in mild stage and 95% in
moderate stage AD, as well as a 96% specificity, for standard MRI
diagnosis [31].
Regarding the hypothetical diagnostic test using MRI with the
new contrast agent (MRI+CLP), we based our assumptions on
available data on PET-scan amyloid imaging. As studies on
amyloid plaques suggest that amyloid deposition reaches a plateau
by the early clinical stages of Alzheimer’s disease (amyloid cascade
hypothesis), we assumed the sensitivity of the MRI+CLP
diagnostic test to be independent of the disease stage. In one
study on PET tracers, the sensitivity and specificity were estimated
at 90% [32]; in another, a 95% sensitivity and 83% specificity
were found [33]. Here, we assumed a 96% sensitivity and 87%
specificity for MRI+CLP.
6. Costs and effectiveness
All costs were measured at their 2009 level.
6.1. Costs of diagnostic tests. The cost of the standard
diagnosis was computed as the sum of the cost of a specialist
consultation in France, estimated at 55J [34], that of mental state
evaluation tests, estimated at 69J [35], and that of standard
laboratory tests, estimated at 50J [36]. The cost of MRI was
obtained from the ‘‘Classification Commune des Actes
Médicaux’’, a fixed-costs scale of medical procedures based on
practitioners’ fees, fixed costs for the medical procedures
themselves, and fixed costs for operating the equipment [35].
Finally, we estimated the cost of the new contrast product for MRI
at 250J [Personal Communication, Guerbet company, Paris,
2009].
6.2. Costs of AD follow-up. Diagnosed AD patients were
assumed to have a follow-up consultation every 6 month with an
AD specialist. These specialist consultations were estimated at 41J
[34].
6.3. Costs of treatment. We used prices for generic AD
drugs, that is, 572J per 6-month period for generic donepezil
(Aricept) and 286J per 6-month period for generic memantine
(Ebixa) [37]. We further assumed that the hypothetical new drug
that would be efficient in early stage AD would have a cost similar
to that of generic donepezil.
Cost-Effectiveness of MRI+CLP for Alzheimer’s
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6.4. Costs of care. We took into account both living and care
costs. For institutionalized patients, living costs included hostel
costs, based on a French study of AD patients [18], and costs of
care included caregiver wages. In an earlier study, caregivers were
estimated to spend 517 hours over a 3 month period caring for
moderate-to-severe AD patients [38]. Here, we therefore
computed costs associated with caregivers over 6 months by
multiplying hourly wages (estimated at 13 J/h for professional
caregivers) with 1034 hours.
For patients living at home, ‘‘basic’’ costs included living and
medical expenditures [39], based on a French study of home-cared
AD patients and controls; the cost of care by unprofessional
caregivers was also estimated as an opportunity cost. In order to do
this, we valued informal care at a conservative value of 8.4 J/h,
and we assumed that these unpaid caregivers spent the same
amount of time caring for AD patients than professional
caregivers, that is, 1034 hours over a 6 month cycle.
6.5. Indirect costs. In this study, we took into account
several indirect costs of AD. First, we assigned an opportunity cost
to unprofessional caregivers who took care of AD patients leaving
at home, as described before.
Second, we took into account the burden of AD care on the
health state of unprofessional caregivers. Based on an earlier study
[38], 35% of AD caregivers take medication related to their
activity; they have high rates of depression and anxiety, as well as
high overall morbidity and mortality rates, compared to non-AD
caregiver controls [40]. We estimated the cost of this health impact
as that as of a weekly psychiatrist consultation, plus that of an
antidepressant treatment, for 35% of unprofessional caregivers.
Finally, we also evaluated the cost associated with the loss of
productivity of AD patients. This is generally not done in cost-
effectiveness studies of AD, since AD patients are for the most part
retired. However, recent data shows that pensioners are becoming
more and more involved in volunteer activities within nonprofit
organizations (NPOs), as well as performing informal volunteer
activities [41].
Here, based on French data [42], we estimated that 60 to 75
year-old individuals performed on average 63.8 hours of informal
volunteering activities over a 6 month period – mostly within the
family sphere, such as childcare for instance. This was valued at
7.7J/hour, which was the minimum wage in France in 2009, and
multiplied by an ‘‘efficiency coefficient’’ of 0.7 to arbitrarily take
into account the reduced productivity in older individuals.
Similarly, we estimated that 50% of 60 to 75 year-old
individuals are involved in NPOs, with a mean of 12 hours of
volunteer activities per month. On average, we hence estimated
that 60 to 75 year-old individuals performed a total of 36 hours of
volunteer activities within NPOs over a 6 month period [43],
which were valued at 7.9J/hour and multiplied by the
aforementioned 0.7 efficiency coefficient.
We added the resulting estimated productivity benefit of a
French pensioner to our analyses as a cost associated to AD, in full
for moderate-to-severe patients and multiplied by 0.6 for mild AD
patients (assuming that mild AD only reduces productivity by
40%).
6.6. Effectiveness. We estimated quality-of-life weights
(QALYs) for over-60 patients without Alzheimer disease at 0.826
on a scale of 0 to 1, on the basis of the mean of time trade-off
scores for men and women aged 65–84 years old published in a
study of health outcomes in the general population [44].
Quality-of-life weights for patients with Alzheimer disease at
each disease stage and care setting (institution or community) were
based on previously published Health Utilities Index Mark 2
(HUI:2) scores [17].
7. Sensitivity analysis
The ranges investigated in the Sensitivity Analysis are
summarized in Table S1, along with the data sources. We
performed both univariate and multivariate sensitivity analyses.
For the multivariate analyses, we performed a Monte-Carlo
simulation with 10.000 trials, using a priori triangular distributions
for model parameters. We then identified the most influential
parameters in the cost-effectiveness of the MRI+CLP strategy by
calculating the partial rank correlation coefficient (PRCC) between
each input parameter and the ICER of this strategy and assessing
their statistical significance.
7.1. Drug effects and prices. We investigated the impact of
the introduction of new drugs, which would have the same costs
and indications as donepezil and memantine, respectively, but
with varying efficacy: the probabilities of transitions under
treatment from mild to moderate or moderate to severe stage
were further reduced by a factor (fmM or fMS) ranging from 0.5 to
1, and the probabilities of transitions under treatment from
moderate to mild or severe to moderate stage were further
increased by a factor (fMm or fSM) ranging from 1 to 2 [17]. For
simplicity reasons, we also summarized these four avenues for
improvement of current AD treatment through a single parameter
f, assuming a linear relationship between the multiplying factors:
f~fML~fSM~{2|fLMz3
Regarding the hypothetical drug efficient for early stage AD
(treatment T), we investigated both more and less efficient drugs,
with probabilities of progression from early to mild and moderate
stage AD under treatment T ranging from 0 to their values
without treatment T; fT was the reduction factor applied to these
transition probabilities due to treatment T (in [0–1]).
The assumed cost for a 6-month cure with treatment T was also
varied, between 0 and 1000J.
7.2. Diagnostic tests characteristics. We investigated
sensitivities from 0.9 to 1 and specificities from 0.7 to 1 in early
to moderate stage AD patients for the hypothetical diagnostic test
using MRI with the CLP contrast product. We also investigated
sensitivities ranging from 0.75 to 0.90 for the standard diagnosis in
moderate stage AD.
In the ‘‘screen and treat’’ analyses, we investigated sensitivities
of standard MRI between 0.1 and 0.5 for early stage AD.
7.3. Disease progression. To model faster or slower
progression of AD, we investigated state transition probabilities
in our Markov model ranging from 10% lower to 10% higher than
their base-case values.
7.4. Initial distribution of patients and prevalence. In
the primary analysis, we investigated AD prevalences among
consulting individuals ranging from 50 to 70%. For each fixed
prevalence, we varied the proportion of patients with mild AD
between 50 and 75% of all AD patients; the ratio between
moderate and severe AD prevalence remained the same, that is,
10 moderate stage patients for 1 severe stage patient.
In the ‘‘screen and treat’’ analyses, we investigated initial AD
prevalences among screened individuals ranging from 1 to 10%.
For each fixed prevalence, we varied the proportion of patients
with early asymptomatic AD from 30 to 75% of all AD patients;
the distribution of mild to severe stages remained the same.
7.5. Discount rate. As the ‘‘screen and treat’’ analyses
spanned a 15 year period, we assessed the impact of variations in
the assumed discount rate for costs and QALYs, from 0 to 10%
per year.
7.6. Frequency of screenings. In the ‘‘screen and treat’’
analyses, we investigated the impact of varying durations between
screening campaigns, ranging from one to ten years.
Cost-Effectiveness of MRI+CLP for Alzheimer’s
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Results
1. Primary analysis
1.1. Base Case. The first part of Table 2 summarizes the
results of the primary cost-effectiveness analysis in the base case; in
the second part of Table 2, hypothetical treatment T is offered to
all MCI patients diagnosed with AD but with high MMSE scores.
In both cases, the standard diagnosis strategy was dominated by
the standard MRI strategy (more costly and less effective).
Cost and effectiveness increased from standard MRI to
MRI+CLP strategies. In the base-case, the ICER of the
MRI+CLP strategy was higher than the French willingness-to-
pay threshold (estimated at 76 171 J/QALY). Hence, standard
MRI was found to be the preferred strategy. However, assuming
that treatment T had been made available led to a lower ICER for
MRI+CLP, making it the preferred strategy.
1.2. Sensitivity analysis. Detailed results of the univariate
sensitivity analysis are presented in Table S2 (without treatment
T). Assuming either more effective AD treatments, higher speed of
AD progression, a larger initial AD prevalence in 70 year-old MCI
individuals, a larger initial portion of mild AD, higher sensitivity or
specificity of MRI+CLP diagnosis or a lower cost of the CLP
product could lead to MRI+CLP becoming the preferred strategy,
with an ICER lower than the willingness-to-pay threshold.
Table 3 (columns 1 and 2) provides partial rank correlation
coefficients (PRCC) between input values and the ICER of the
MRI+CLP strategy (compared with the standard MRI strategy,
without treatment T). Only parameters whose PRCC with this
ICER is statistically significant at the confidence level of 5% or
lower are shown, namely: the speed of disease progression; the
initial AD prevalence in the studied population; the initial portion
of mild stage AD; the discount rate; the sensitivity and specificity of
the MRI+CLP diagnostic test; and the cost of the CLP contrast
agent.
In Figure 2, the sensitivity of our conclusions on the MRI+CLP
diagnostic test characteristics (sensitivity, specificity and cost) is
assessed. MRI+CLP is the preferred strategy in a wide array of
scenarios, including some assuming lower sensitivity or specificity
or higher cost than in the base-case.
Figure S2 provides the distribution of incremental cost-
effectiveness ratios for the MRI+CLP strategy, compared with
standard diagnosis, as well as an acceptability curve depicting the
probability for each of the three investigated strategies to be
preferred as a function of the willingness-to-pay threshold. For
willingness-to-pay thresholds larger than 90 000J/QALY,
MRI+CLP becomes the preferred strategy.
With the assumed WTP threshold at 76 171J/QALY, the
probability that MRI+CLP was the preferred strategy increased
from 43% to 64% when treatment T was assumed to be available
(data not shown). Figure S3 investigates the impact of the efficacy
and cost of treatment T on these results.
2. ‘‘Screen and treat’’ analyses
2.1. Base Case. Table 4 summarizes the results of the
‘‘screen and treat’’ cost-effectiveness analyses in the base case; in
the first part, the whole over-60 population is screened, while in
the second part, the screening is targeted at ApoE4 individuals. In
both cases, the standard diagnosis strategy was dominated by the
standard MRI strategy.
Table 3. Partial rank correlation coefficients (PRCC) between input values and the ICER of the MRI+CLP strategy (compared with
the preferred strategy).
Primary cost-effectiveness analysis ‘‘Screen and treat’’ cost-effectiveness analysis (population-wide screening)
Parameter PRCC Parameter PRCC
Speed of disease progression 20,41 Initial prevalence of AD 20,86
Initial prevalence of AD 20,51 Initial portion of early AD 20,15
Initial portion of mild AD 20,26 Sensitivity of MRI+CLP test 20,17
Sensitivity of MRI+CLP test 20,92 Specificity of MRI+CLP test 20,64
Specificity of MRI+CLP test 20,73 Discount rate 0,29
Discount rate 0,19 Cost of the CLP contrast agent 0,41
Cost of the CLP contrast agent 0,79 Cost of treatment T 0,78
Impact of treatment T (from high to low) 0,41
Speed of disease progression 20,23
Sensitivity of standard MRI in early AD 0,51
All PRCCs are statistically significant at the confidence level of 5%. A higher absolute value of PRCC indicates a strong relationship between that parameter and the ICER;
a positive (resp. negative) value of PRCC implies that the value of the ICER increases (resp. decreases) when the value of the input increases.
doi:10.1371/journal.pone.0035559.t003
Table 2. Results of the primary analysis (base-case
hypothesis): computed cost, efficacy and cost-effectiveness
(C/E) ratio of the standard diagnosis, standard MRI and
MRI+CLP strategies, and incremental cost-effectiveness ratios
(ICER) of the MRI+CLP strategy as compared with the standard
MRI strategy.
Strategy Cost (in J)
Efficacy (in
QALYs) C/E ICER
In the current context
Standard diagnosis 36 294 1.7663 20 548 Dominated
Standard MRI 36 131 1.7710 20 401
MRI+CLP 36 313 1.7731 20 480 88 439 J/QALY
Assuming hypothetical treatment T has been made available
Standard diagnosis 36 260 1.7668 20 523 Dominated
Standard MRI 36 117 1.7712 20 391
MRI+CLP 36 268 1.7737 20 447 60 923 J/QALY
doi:10.1371/journal.pone.0035559.t002
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Although overall computed costs and QALYs were lower when
assuming a screening targeted at the ApoE4 population, the main
base-case results were similar in both our screening analyses. The
MRI+CLP strategy was both more costly and more efficient than
the standard MRI strategy. Its ICER, compared with the standard
MRI strategy, was much higher than the French willingness-to-pay
estimated at 76 171 J/QALY. Therefore, standard MRI was the
preferred strategy in the base case.
2.2. Sensitivity analysis. Detailed results of the univariate
sensitivity analysis are presented in Table S3 for the population-
wide screening scenario. For an assumed specificity of MRI+CLP
higher than 98%, MRI+CLP became the preferred strategy; it was
strongly dominant for specificities over 99%. No other individual
model parameter had enough impact on our results to make
MRI+CLP the preferred strategy.
Table 3 (columns 3 and 4) provides partial rank correlation
coefficients (PRCC) between inputs values and the ICER of the
MRI+CLP strategy (compared with the standard MRI strategy),
for the population-wide screening scenario. Only parameters
whose PRCC with this ICER is statistically significant at the
confidence level of 5% or lower are shown, namely: the initial AD
prevalence in the studied population; the specificity of the
MRI+CLP diagnostic test; and the efficacy and cost of new
treatment T.
Figure 3 depicts results from a multivariate analysis performed
on the efficacy and cost of the hypothetical new treatment and
MRI+CLP specificity, while Figure 4 depicts results from a
multivariate analysis performed on the initial prevalence of AD in
the general over-60 population, the specificity of MRI+CLP
diagnosis and the assumed cost of the CLP contrast agent. Several
combinations of these parameters allow for MRI+CLP strategy
dominance, but all include high specificity of MRI+CLP diagnosis.
For instance:
– assuming 98% specificity for MRI+CLP diagnosis and that
treatment T reduces AD progression from the early stage by
half, MRI+CLP is the preferred strategy for the base-case cost
of treatment T (500J/6 months of treatment)
– assuming an initial AD prevalence of 4% and the base-case cost
of 250J per injection for the CLP contrast agent, MRI+CLP is
the preferred strategy as long as MRI+CLP diagnosis is more
than 97% specific.
Figure S4 provides the distribution of incremental cost-
effectiveness ratios for the MRI+CLP strategy, compared with
standard MRI, as well as an acceptability curve depicting the
probability for the MRI+CLP strategy to be the preferred strategy
as a function of the willingness-to-pay threshold. This probability
remains lower than 4% even assuming a willingness-to-pay at
200 000J/QALY.
When assuming a screening targeted at the ApoE4 population,
the probability that MRI+CLP was the preferred strategy
increased slightly, reaching 5% for a 200 000 J/QALY
willingness-to-pay threshold (data not shown).
Discussion
Here, we investigated the cost-effectiveness of a new diagnostic
tool for AD allowing early diagnosis in two different contexts. First,
we assumed that this new diagnostic tool would be made available
to the same individuals who are currently offered other diagnostic
tests. Second, we hypothesized that a treatment with significant
efficacy in early stage AD was developed, and that, as a
consequence, a national screening campaign was put into place,
using either the currently available diagnostic tests or the new
diagnostic test.
We found that in both analyses, the preferred base-case strategy
was the standard MRI strategy. However, multivariate sensitivity
analyses showed that, while in the primary analysis combining
MRI with a new contrast product could prove the preferred
strategy under a wide array of realistic scenarios, the probability of
this happening was inferior to 5% in the hypothesis of a national
screening campaign. Even assuming the availability of a low-cost
highly efficient treatment in early AD, novel contrast agents would
need to have very high specificity to be cost-effective when used for
systematic screening of the entire population.
1. Models of disease progression
We used Markov models of AD progression. Although widely
used in similar cost-effectiveness analyses [10,11,17,18,45,46], this
approach presents several limitations. First, it has been shown that
using time-independent transition probabilities may lead to either
overestimate or underestimate disease progression, depending on
the AD stage [47]. Second, in order for the model complexity to
remain manageable, we were led to limit the number of states. In
order to take into account indirect consequences of AD, such as
the loss of productivity of AD patients in their volunteer activities,
we incorporated them as aggregate factors in the computation of
costs.
Using other modeling approaches, such as discrete events
simulation, would allow a more detailed and realistic description of
AD progression and, in turn, derive more reliable conclusions
[12,48].
Figure 2. Results of the primary analysis: multivariate sensitivity analysis. The strategy with maximum net monetary benefit is depicted as
a function of the assumed sensitivity and specificity of the MRI+CLP diagnostic test, for assumed costs of the CLP contrast agent between 0 and 500J
per injection (in the absence of treatment T): (a) Cost of the CLP contrast agent at 50 J/injection. (b) Cost of the CLP contrast agent at 250 J/
injection. (c) Cost of the CLP contrast agent over 450 J/injection.
doi:10.1371/journal.pone.0035559.g002
Table 4. Results of the ‘‘screen and treat’’ analyses (base-case
hypothesis): computed cost, efficacy and cost-effectiveness
(C/E) ratio of the standard diagnosis, standard MRI and
MRI+CLP strategies, and incremental cost-effectiveness ratio
(ICER) of the MRI+CLP strategy as compared with the standard
MRI strategy.
Strategy Cost (in J)
Efficacy (in
QALYs) C/E ICER
Population-wide screening
Standard diagnosis 43 559 8.0722 5 396 Dominated
Standard MRI 43 009 8.0732 5 327
MRI+CLP 44 945 8.0752 5 566 991 972 J/QALY
Screening targeted at ApoE4 individuals
Standard diagnosis 44 711 8.0377 5 563 Dominated
Standard MRI 44 180 8.0386 5 496
MRI+CLP 46 075 8.0415 5 730 641 326 J/QALY
doi:10.1371/journal.pone.0035559.t004
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2. Assumed properties of the MRI+CLP diagnostic test
Because the new CLP contrast agent for MRI is still under
development, assumptions had to be made regarding its sensitivity
and specificity for diagnosing AD. As mentioned in the Methods,
we based these assumptions in part on available data on PET-scan
used with amyloid markers [32,33]. We also investigated relatively
wide ranges for these characteristics in our sensitivity analyses.
Regarding the specificity, it should be noted that amyloid
plaques have been detected in 10 to 30% of otherwise apparently
normal elderly subjects. This may limit the capacity of MRI+CLP
to correctly identify healthy subjects, which is why we investigated
specificities as low as 0.70 in our sensitivity analyses. However,
several studies also suggest that the presence of amyloid plaques is
associated with declining cognitive test scores and with structural
and functional brain changes suggestive of early AD [49]. In two
recent follow-up studies, about one third of patients with mild
cognitive impairment in whom amyloid plaques were detected
converted to AD over the following 2 years [50,51]. It could
therefore be argued that at least part of these 10–30% amyloid-
positive individuals may not be ‘‘false positive’’, but very early
stage AD patients.
Figure S5 illustrates the influence of false positives and false
negatives associated with the MRI+CLP diagnosis in terms of
additional cost per QALY in both our primary analysis and our
‘‘screen and treat’’ analysis.
3. Included costs
In this study, we chose to include indirect costs in addition to
direct costs. The importance of these indirect costs, which include
costs associated with the loss of productivity of AD patients and
costs associated with informal caregiving at the homes of AD
patients, has indeed been underlined in several recent studies,
which showed that they may dominate direct costs of care in early
stages of the disease [52]. As a consequence, it has been suggested
in recent reviews that future cost-effectiveness studies should take
into account such indirect costs [48,53].
4. Results and limits of the primary analysis
The results we obtained in our primary analysis are similar to
those from previously published cost-efficacy studies, in the sense
that in the base-case, adding a new marker to MRI was not cost-
effective [10,11]. However, in our multivariate sensitivity analysis,
there was a high probability of MRI+CLP becoming the preferred
strategy.
In addition, it is to be noted that we found the standard MRI
strategy to dominate the standard diagnosis strategy, whereas
earlier studies found very high ICERs for similar imaging
strategies [10,11]. This may be due to the fact that in these
earlier studies, MRI was supposed to come as an addition to the
standard diagnosis procedure, which included a detailed history, a
questionnaire test such as the MMSE, laboratory testing and
nonenhanced CT imaging. In our study, the standard MRI
strategy only comprised the initial specialist consultation, the
MMSE and MRI itself.
Because of the high level of uncertainty surrounding the
assumed sensitivity and specificity of both standard diagnosis and
standard MRI, we also explored how our results changed when
assuming higher sensitivity and specificity for the standard
diagnosis, or lower sensitivity and specificity for standard MRI.
Irrespective of the assumed specificity, the standard diagnosis
strategy remained dominated by the standard MRI strategy.
However, as shown in Figure S6, standard diagnosis could become
preferable to standard MRI under a wide array of combinations of
lower sensitivity for standard MRI and higher sensitivity for
standard diagnosis in moderate AD.
All in all, it should be underlined here that comparing standard
MRI to the current standard diagnosis strategy for AD was not the
focus of this study and that our results should not be taken as
evidence that large-scale screening using standard MRI should be
undertaken.
Several limitations of this analysis lie with the assumptions we
made on AD treatment.
First, we neglected all adverse effects from the treatments.
Including a cost associated with such adverse effects in treated
individuals would lead to reduced ICERs for all strategies. As costs
would be expected to increase while QALYs remained unchanged,
the ICER of the MRI+CLP strategy should only increase.
Second, we assumed that all diagnosed individuals were treated.
This is in reality probably false, as AD patients may end up
rejecting treatment or not taking it properly.
Finally, another limitation of this analysis is that we did not take
into account the psychological impact of early diagnosis of AD in
the absence of efficient treatment at this stage. Including this factor
would increase the cost associated to the MRI+CLP strategy, and
in turn its ICER.
5. Results and limits of the ‘‘screen and treat’’ analyses
In our ‘‘screen and treat’’ analyses, we investigated a
hypothetical future in which new treatments effective in early
stage AD were available. To our knowledge, ours is the first study
to do so, although earlier works investigated improvements in
currently available treatments for mild to severe stage AD [10,11].
Innovatively, this second analysis also included a community-wide
screening program and repeated rounds of testing. Indeed, if such
treatments were to become available, population screening
programs – which are not currently recommended by any health
Agency – would have to be discussed.
Because the investigated context was hypothetical, we had to
make several assumptions which influenced our results. First, we
had to estimate the prevalence of AD in the general over-60
population, including asymptomatic cases. There is obviously no
data to document this prevalence, and we chose a rather
conservative value of 1%; the actual figure may be well over this
value and we investigated prevalences up to 10% in our sensitivity
analysis. Our base-case analysis was a worst-case scenario for the
MRI+CLP strategy, which included the only diagnosis tool
adapted to early AD.
Second, as both the new treatment and the new diagnosis test
were hypothetical, we chose values for their base-case character-
istics based on personal communications with AD specialists and
teams currently working on the development of CLP tracers
[Personal Communication, Guerbet company, Paris, 2009], and
Figure 3. Results of the ‘‘screen and treat’’ (population-wide screening) analysis: multivariate sensitivity analysis. The strategy with
maximum net monetary benefit is depicted as a function of the assumed efficacy and cost of the hypothetical new drug T, for assumed specificities of
the MRI+CLP diagnosis test between 0.80 and 0.99. The efficacy of treatment T is expressed as a 0-to-1 ratio between assumed probabilities of
transition from early stage AD with and without treatment T; 0 corresponds to maximum efficacy and 1 to no efficacy (in the base case, fT = 0.5: 50%
reduction). Only costs lower than the base-case cost of 500J per 6-month treatment are investigated here. (a) specificity for MRI+CLP inferior to 0.97
(including base case). (b) 0.98 specificity for MRI+CLP. (c) 0.99 specificity for MRI+CLP.
doi:10.1371/journal.pone.0035559.g003
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investigated wide ranges of variation for these values in our
sensitivity analysis. It is to be noted that the new treatment T may
well be more expensive than 1000J, the top limit of our
investigated range; however, as shown by our results, MRI+CLP
would then systematically not prove cost-effective, irrespective of
other characteristics.
Third, the participation rate to the screening campaign was
unknown, and assumed to be 100%. Based on observed data from
similar screening campaigns, actual rates are more around 60% at
best, meaning that the screened population may not be
representative of the general over-60 population. Also, being
screened positive for AD may have a psychological impact,
especially in asymptomatic patients. We chose not to take into
account this impact in our analysis, considering that it should be
reduced by the availability of a treatment efficient from early AD.
Future studies should model screening participation and impact
more realistically and investigate the potential repercussions.
Finally, this second analysis suffered from the same limitations
related to AD treatment as the first. Including adverse effects of
treatments in this analysis would increase the cost of the
MRI+CLP strategy. Moreover, as the time horizon for this
analysis was 15 years, it would have been interesting to investigate
the impact of varying durations of treatment efficacy. This will be
made easier in future years when more data on the long-term
impact of AD treatment becomes available.
Because there is evidence that individuals carrying the ApoE4
gene are at increased risk for AD, we felt it was pertinent to
investigate a scenario under which screening was targeted at these
individuals. It should be noted however, that, in order to fully
investigate such a scenario, other factors may have to be taken into
account. Indeed, some epidemiological studies suggest that the
ApoE4 genotype increases mortality rates, in particular cardio-
vascular mortality in older individuals [54], hence age-specific
mortality rates would need to be obtained for ApoE4 individuals.
In addition, amyloid plaque density in cognitively healthy adults
has been shown to be higher in ApoE4 carriers [55]. Depending
on the interpretation of this finding, this may have different
implications for a diagnostic tool based on the detection of amyloid
plaques. On the one hand, it could be assumed that ApoE4
carriage increases the speed of amyloid plaque accumulation in
AD patients; in that case, MRI+CLP would have better sensitivity
in early stage AD in ApoE4 carriers. On the other hand, it could
also be assumed that the ApoE4 genotype increases the density of
amyloid plaques irrespective of AD; in that case, MRI+CLP would
be expected to have lower specificity in ApoE4 carriers.
6. Conclusions
Assuming that a treatment with proven efficacy in early AD
becomes available, as well as a diagnostic test allowing early
detection of the disease, the issue of screening the population will
arise. Our study suggests that, in order for this screening to be cost-
effective, key parameters are the specificity of the new diagnostic
test and the cost and effectiveness of the new treatment. These
preliminary results ought to be taken into account in the currently
underway research on early detection and treatment of AD,
including work on b-amyloid plaques detection and elimination.
When this research yields results, a new cost-effectiveness
analysis should be performed in order to evaluate the available
tools with observed data.
Supporting Information
Figure S1 Markov models of Alzheimer’s disease pro-
gression. All states are further subdivided in two, for individuals
living at home vs. inside an institution (retirement or nursing
home). A) Model for the primary analysis. B) Model for the
‘‘screen and treat’’ analyses.
(TIF)
Figure S2 Multivariate sensitivity analysis of the pri-
mary cost-effectiveness study. A) Distribution of incremental
cost-effectiveness ratios (ICER) of the MRI+CLP strategy,
compared to the standard diagnosis strategy. B) Acceptability
curve: probability that each strategy either is dominant or has an
ICER inferior to the willingness-to-pay, as a function of the
willingness-to-pay threshold.
(TIF)
Figure S3 Multivariate sensitivity analysis of the pri-
mary cost-effectiveness study with treatment T. The
strategy with maximum net monetary benefit is depicted as a
function of the assumed efficacy and cost of the hypothetical new
drug T. The efficacy of treatment T is expressed as a 0-to-1 ratio
between assumed probabilities of transition from early stage AD
with and without treatment T; 0 corresponds to maximum efficacy
and 1 to no efficacy (in the base case, fT = 0.5: 50% reduction).
(TIF)
Figure S4 Multivariate sensitivity analysis of the
‘‘screen and treat’’ (population-wide screening) cost-
effectiveness study. A) Distribution of incremental cost-
effectiveness ratios (ICER) of the MRI+CLP strategy, compared
to the standard MRI strategy. B) Acceptability curve: probability
that the MRI+CLP strategy either is dominant or has an ICER
inferior to the willingness-to-pay, as a function of the willingness-
to-pay threshold.
(TIF)
Figure S5 Analysis of the influence of MRI+CLP false
positives and false negatives on the cost-effectiveness of
the MRI+CLP strategies (tornado diagram). The range of
incremental cost-effectiveness ratios (ICER) of the MRI+CLP
strategy (compared to the standard MRI strategy) in A) the
primary analysis and B) the ‘‘screen and treat’’ analysis is depicted
for MRI+CLP sensitivities ranging from 0.9 to 1 and specificities
ranging from 0.7 to 1. A sensitivity lower than 0.96 (base-case
value) implies a higher risk of false negatives (FN, dotted green
bars) than in the base-case. A specificity lower than 0.87 (base-case
value) implies a higher risk of false positives (FP, dotted yellow
bars) than in the base-case.
(TIF)
Figure S6 Multivariate sensitivity analysis of the results
of the primary cost-effectiveness study on standard MRI
vs. standard diagnosis. The strategy with maximum net
monetary benefit among these two strategies is depicted as a
Figure 4. Results of the ‘‘screen and treat’’ (population-wide screening) analysis: multivariate sensitivity analysis. The strategy with
maximum net monetary benefit is depicted as a function of the assumed prevalence of AD in the general over-60 population (between 0 and 10%)
and specificity of the MRI+CLP diagnostic test between 0.90 and 1, for assumed costs of the CLP contrast agent between 0 and 500J per injection: (a)
Cost of the CLP contrast agent at 50 J/injection. (b) Cost of the CLP contrast agent at 250 J/injection (base-case). (c) Cost of the CLP contrast agent
at 500 J/injection.
doi:10.1371/journal.pone.0035559.g004
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function of the assumed sensitivity of the standard MRI diagnostic
test in mild and moderate AD, for an assumed sensitivity of the
standard diagnosis strategy in moderate AD between 0.75 and
0.85 (in the absence of CLP and treatment T). A) 0.75 sensitivity in
moderate AD for standard diagnosis (base-case value). B) 0.85
sensitivity in moderate AD for standard diagnosis.
(TIF)
File S1 Models of disease progression.
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Table S1 Model parameters: base-case values and
ranges investigated in the sensitivity analyses.
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Table S2 Univariate sensitivity analysis: incremental
cost-effectiveness ratio (ICER) of the MRI+CLP strategy,
compared to the reference strategy, in the primary cost-
effectiveness analysis, depending on the values of model
parameters.
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Table S3 Univariate sensitivity analysis: ICER of the
MRI+CLP strategy compared with the reference strate-
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